Sumatriptan in clinical practice: A 2-year review of 453 migraine patients

Neurology

Volumn 47, Issue 1, 1996, Pages 46-51

  Visser, W Hester ^a   De Vriend, Rolf H M ^a   Jaspers, Natasja M W H ^a   Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; ANALGESIA; ANXIETY; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX PAIN;

EID: 0030055536     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.46     Document Type: Article

References (30)

1. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.
2. Pilgrim AJ. The clinical profile of sumatriptan: efficacy in migraine. Eur Neurol 1994;34(suppl 2):26-34.
3. Wilkinson M, Pfaffenrath V, Schoenen J, Diener H-C, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-357.
4. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994;14:330-338.
5. Rapoport AM, Visser WH, Cutker NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995;45:1505-1509.
6. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991;31:339-344.
7. Tansey MJB, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol 1993;33:310-315.
8. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol 1994;34(suppl 2):40-43.
9. Tansey MJB, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1993;114:109-116.
10. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
11. Sheftell FD, Weeks RE, Rapoport AM, Siegel S, Baskin S, Arrowsmith F. Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center. Headache 1994;34:67-72.
12. Dahlöf C, Ekbom K, Persson L. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol 1994;51:1256-1261.
13. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994;34:319-328.
14. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994;34(suppl 2):6-11.
15. Rasmussen BK, Breslau N. Epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headache. New York: Raven Press, 1993:169-173.
16. Staffa JA, Lipton RB, Stewart WF. The epidemiology of migraine headache. Rev Contemp Pharmacother 1994;5:241-252.
17. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-322.
18. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-926.
19. 1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995;2:5-21.
20. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled dose-range finding study. Neurology 1996;46:522-526.
21. Dahlöf C. Headache recurrence after subcutaneous sumatriptan. Lancet 1992;339:425-426.
22. Rasmussen BK, Jensen R, Olesen J. Questionnaire versus clinical interview in the diagnosis of headache. Headache 1991;31:290-295.
23. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993; 14:129-133.
24. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
25. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-294.
26. Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR. Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992;52:635-642.
27. Catarci T, Fiacco F, Argentine C, Sette G, Cerbo R. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994;14:374-375.
28. Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan. BMJ 1994;308:1573-1574.
29. Osborne MJ, Austin RCT, Dawson KJ, Lange L. Is there a problem with longterm use of sumatriptan in acute migraine? BMJ 1994;308:113.
30. Gaist D, Sindrup S, Hallas J, Gram LF. Misuse of sumatriptan. Lancet 1994;344:1090.